Antibodies to watch in 2024
ABSTRACTThe ‘Antibodies to Watch’ article series provides an annual summary of commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical development, regulatory review, and those recently granted a first approval in any country. In this installment, we discuss key deta...
Main Authors: | Silvia Crescioli, Hélène Kaplon, Alicia Chenoweth, Lin Wang, Jyothsna Visweswaraiah, Janice M. Reichert |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2023.2297450 |
Similar Items
-
Antibodies to watch in 2023
by: Hélène Kaplon, et al.
Published: (2023-12-01) -
Biosimilars in India; current status and future perspectives
by: Bikash R Meher, et al.
Published: (2019-01-01) -
Factors Affecting Antibody-Mediated Immune Response and Cellular-Mediated Immune Response in Weaned Brahman Calves
by: Christian L. Young, et al.
Published: (2023-11-01) -
Animal- versus in vitro-derived antibodies: avoiding the extremes
by: Andrew R.M. Bradbury, et al.
Published: (2021-01-01) -
Alternative Routes of Administration for Therapeutic Antibodies—State of the Art
by: Aubin Pitiot, et al.
Published: (2022-08-01)